GlassScriptPhysician profile
Casey D Claypool
NPI 1447480579
$323,442.01
in general payments reported to CMS, 2019-2025
33 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $35K · 2021: $24K · 2022: $44K · 2023: $37K · 2024: $74K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $88K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $24K · Food and Beverage: $10K · Consulting Fee: $8,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $87,512.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,703.66 |
| Travel and Lodging | $23,635.17 |
| Food and Beverage | $10,443.49 |
| Consulting Fee | $8,187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $87,814.30 | 2019-2025 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator, Lipiview Ocular Surface Interferometer |
| Bausch & Lomb Americas INC. | $76,493.19 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Sun Pharmaceutical Industries INC. | $57,667.36 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Tarsus Pharmaceuticals, INC. | $50,478.95 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $17,208.30 | 2021-2025 | |
| Abbvie INC. | $15,627.74 | 2022-2025 | Vuity, Lumigan, Durysta |
| Allergan, INC. | $11,481.61 | 2020-2022 | |
| Lumenis, INC | $2,000.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $814.26 | 2020-2025 | Acthar |
| Glaukos Corporation | $633.69 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $424.41 | 2019-2022 | |
| Dompe US, INC. | $416.59 | 2019-2025 | Oxervate |
| Alcon Vision LLC | $380.21 | 2022-2025 | Tryptyr, Rocklatan, Simbrinza |
| Mallinckrodt Enterprises LLC | $350.07 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $345.30 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $324.78 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Shire North American Group INC | $184.46 | 2019 | |
| Aerie Pharmaceuticals, INC. | $172.78 | 2019 | |
| Rxsight INC | $124.91 | 2022 | |
| Merz Pharmaceuticals, LLC | $96.98 | 2021-2025 | Xeomin |
| Carl Zeiss Meditec, INC. | $60.36 | 2019 | |
| Thea Pharma INC. | $47.88 | 2022-2023 | Iyuzeh |
| Johnson & Johnson Vision Care, INC. | $44.23 | 2019 | |
| Lumibird Medical INC. | $40.09 | 2025 | |
| Astellas Pharma US INC | $34.44 | 2024 | Izervay |
| Harrow Eye, LLC | $32.36 | 2025 | Vevye |
| Genentech USA, INC. | $30.57 | 2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2023 | Eylea |
| Carl Zeiss Meditec USA, INC. | $23.66 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.67 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $15.93 | 2023 | Tepezza |
| Ivantis, INC | $15.37 | 2020 | |
| Sight Sciences, INC. | $12.97 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Claypool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.